Forte Capital’s Teva Pharmaceuticals TEVA Stock Holding History

Forte Capital’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-6,634	Closed	-$382K	–	159
2014 Q4	$382K	Hold	6,634	–	–	0.17%	120
2014 Q3	$357K	Buy	+6,634	New	+$351K	0.16%	120

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

MIP

Mondrian Investment Partners London, United Kingdom $6.69B AUM

PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

Forte Capital's TEVA Position: Q1 2015 in Review

Forte Capital sold out of Teva Pharmaceuticals (TEVA) in Q1 2015, closing a stake of 6,634 shares — an estimated $382K sold.

Forte Capital first reported a position in TEVA in Q3 2014 and held it in 2 quarters. The position peaked at $382K in Q4 2014. 821 funds tracked by Wall St. Rank hold TEVA as of Q1 2015.

Forte Capital reported no remaining Teva Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
Forte Capital sold 6,634 Teva Pharmaceuticals shares in Q1 2015, an estimated $382K.
Forte Capital first reported a position in Teva Pharmaceuticals in Q3 2014 and held it in 2 quarters.
Forte Capital's Teva Pharmaceuticals position peaked at $382K in Q4 2014.
821 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2015.

Based on Forte Capital's 13F filing for Q1 2015, filed 13 Apr 2015.